Wolfe Research Upgrades Warner Bros. Discovery as Max Sees Improvement
Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wolfe Research
Wolfe Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a strong-buy rating in a report ...
Fintel on MSN2d
Wolfe Research Initiates Coverage of Eli Lilly and (LLY) with Outperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Eli Lilly and (NYSE:LLY) with a Outperform ...
Fintel on MSN2d
Wolfe Research Initiates Coverage of BioMarin Pharmaceutical (BMRN) with Outperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of BioMarin Pharmaceutical (NasdaqGS:BMRN) with a ...
Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’
Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...
Amgen (NASDAQ:AMGN) Research Coverage Started at Wolfe Research
Wolfe Research started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report published on Friday, MarketBeat reports. The brokerage issued a peer perform rating on the medical research ...
Veracyte initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Veracyte (VCYT) with an Outperform rating and $50 price target Published first on TheFly – the ...
Wolfe upgrades Warner Bros. Discovery as trends at Max improve
Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...
Investing3d
Wolfe Research sets stock target on Veracyte, cites growth potential
On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte ...
Seeking Alpha3d
U.S. Pharma is largely immune from 'MAHA' impact: Wolfe
Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic disease movement "Make America Healthy Again," championed by Robert F.
Nasdaq3d
Wolfe Research Initiates Coverage of AbbVie (SNSE:ABBVCL) with Outperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (SNSE:ABBVCL) with a Outperform recommendation. What is the Fund Sentiment? There are 4,922 funds or ...
Nasdaq3d
Wolfe Research Initiates Coverage of Amgen (SNSE:AMGNCL) with Peer Perform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Amgen (SNSE:AMGNCL) with a Peer Perform recommendation. There are 4,117 funds or institutions reporting positions in ...